What did @desschnell actually say?
In a 1.1 million-view TikTok, @desschnell documented picking up her first Mounjaro prescription and walked viewers through exactly how she got it: a telehealth app called Push Health, about $60, a brief intake form, a doctor call within an hour, and a prescription in two hours. She noted the doctor asked about family history of thyroid cancer, ordered labs, and also sent a Zofran prescription. She described Mounjaro as "a shot that you put in your stomach once a week" and said it was "just approved in July by the FDA for diabetics" but "hasn't been approved for just like weight loss yet." She was surprised her insurance approved the medication even though she said, "I'm not diabetic... I don't have any of the things that insurance would approve."
This video is candid, personal, and racked up serious reach. That makes the factual accuracy matter a lot.
Does the science back this up?
On the mechanism and indications, she's mostly in the right ballpark, but some key dates and details are off. Tirzepatide (brand name Mounjaro) was FDA-approved for type 2 diabetes management in May 2022, not July. The July 2022 date she references may reflect when she personally started researching, not an approval date. A separate tirzepatide formulation, Zepbound, was approved specifically for chronic weight management in November 2023.
On the clinical side, tirzepatide is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found participants without diabetes lost an average of 20.9% of body weight over 72 weeks at the highest dose. That is a real and substantial effect, not hype. The SURPASS trial series confirmed A1C reductions of up to 2.6 percentage points in people with type 2 diabetes (Frías et al., 2021, New England Journal of Medicine). These are legitimate clinical outcomes. The drug works. The question is whether the prescribing process she described was adequate, and that is where things get more complicated.
What did they get wrong (or right)?
She got the drug class right. Mounjaro is a weekly injectable. It is used for diabetes and off-label for weight loss. Zofran as an anti-nausea co-prescription is clinically reasonable; GI side effects are among the most common adverse events with tirzepatide, reported in over 30% of patients in SURMOUNT-1.
What she got wrong: the FDA approval date. Mounjaro's type 2 diabetes approval was May 2022, not July. This is a minor error, but in a video that 1.1 million people watched, minor errors compound.
What is genuinely concerning here is the prescribing process she described. A two-hour turnaround, a few questions about thyroid cancer history, and a prescription sent to pharmacy is a thin clinical workup for a medication with real contraindications, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome, pancreatitis risk, and the need for baseline metabolic evaluation. The American Diabetes Association and prescribing guidelines recommend a more thorough intake. Asking about thyroid cancer is correct, but it is not sufficient on its own. Ordering labs she had not yet completed before sending the prescription is also worth flagging as a sequencing concern.
What should you actually know?
Tirzepatide is a legitimate, well-studied medication with strong clinical trial data. Off-label prescribing for weight loss is legal and common. None of that is the problem here. The problem is that the prescribing pathway she described, fast, low-friction, based primarily on what she saw on her For You page, is exactly the kind of telehealth model that regulatory bodies and clinicians have raised concerns about.
The FDA issued a warning in 2023 about compounded tirzepatide products, noting quality and dosing risks. Mounjaro from a licensed pharmacy is brand-name tirzepatide, which is different from compounded versions circulating through some online platforms. That distinction matters and is worth knowing before you buy anything.
- Tirzepatide has real side effects beyond nausea: pancreatitis, gallbladder disease, tachycardia, and potential thyroid C-cell tumors in animal studies (though human risk remains under study).
- Insurance approval for Mounjaro without a diabetes diagnosis is unusual and may depend on diagnosis codes used during prescribing. If you are in this situation, it is worth asking your prescriber what diagnosis was submitted.
- A regulated telehealth platform should conduct a thorough medical history review, not just a thyroid cancer question, before prescribing any GLP-1 or GIP/GLP-1 agonist.